Par Pharmaceutical Sued by Horizon Over Duexis Generic

Par Pharmaceutical Cos. was sued for patent infringement by Horizon Pharma Inc. (HNP) over a generic version of the drug Duexis, used to treat arthritis.

Horizon, based in Northbrook, Illinois, contends Par plans to market a copy of the drug before two U.S. patents expire in 2026, according to a complaint filed yesterday in federal court in Wilmington, Delaware.

Unless a judge stops the alleged infringement, “Horizon will be irreparably harmed,” the company said in court papers.

Gross sales for Duexis in the third quarter of 2012 were $3 million, Horizon said in a Nov. 13 statement.

Stephen Mock, a spokesman for Woodcliff Lake, New Jersey- based Par, didn’t immediately return a phone call seeking comment on the lawsuit.

The case is Horizon Pharma v. Par Pharmaceutical, U.S. District Court, District of Delaware (Wilmington).

To see the patents in the lawsuit, click: 8,309,127 and 8,318,202.

To contact the reporter on this story: Phil Milford at pmilford@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.